- UroToday Home
- Urologic Oncology
Prostate Cancer Abstracts and Beyond
Recent Abstracts
-
Adding Immunotherapy to Radiation Improves Disease-Free Survival in Localized Prostate CancerProstate CancerJune 5, 2026
-
Impact of Prior Treatments on Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer: A Real-World Analysis in the United States.Prostate CancerJune 5, 2026
-
A harmonized single-cell RNA-seq atlas of human localized and metastatic prostate cancers and benign tissues.Prostate CancerJune 5, 2026
-
Focal Cryo-ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer.Prostate CancerJune 5, 2026
-
Clinico-genomic nomograms for estimation of survival risk in metastatic castrate-resistant prostate cancer.Prostate CancerJune 5, 2026
-
Stage-Specific Regulation of DNA Damage Repair by the Circadian Regulator, CRY1, in Prostate Cancer.Prostate CancerJune 5, 2026
-
Progression-free survival following primary staging with [¹⁸F]PSMA-1007-PET/ceCT versus Na[¹⁸F]F-PET/ceCT in prostate cancer: Results from the PRISMA-PET randomized controlled trialProstate CancerJune 4, 2026
-
One-Year Functional Satisfaction and Quality of Life Outcomes of Patients With a History of Radiotherapy With Artificial Urinary Sphincters.Prostate CancerJune 4, 2026
-
Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate Cancer.Prostate CancerJune 4, 2026
-
Beyond GnRH analogues: The Renaissance of Estrogens in Prostate Cancer Management.Prostate CancerJune 4, 2026
Beyond the Abstracts
-
Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial - Beyond the AbstractProstate CancerJune 4, 2026
-
Associations Between Medicaid Insurance, Facility Medicaid Share, and Guideline-Concordant Prostate Cancer Care - Beyond the AbstractProstate CancerJune 3, 2026
-
Identification of Biomarkers Predictive of Successful Salvage Surgery in Prostate-specific Membrane Antigen Positron Emission Tomography-positive Oligorecurrent Prostate Cancer: Results from the BioPoP Trial - Beyond the AbstractProstate CancerMay 26, 2026
-
Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review - Beyond the AbstractProstate CancerMay 26, 2026
-
Therapeutic Targeting of Prostate-Specific Membrane Antigen Could Limit Its Potential as Benchmark Imaging - Beyond the AbstractProstate CancerMay 20, 2026
-
Phase II Trial of Combination Radiation, Hormone, and Immunotherapy in Grade Group 5 Prostate Cancer - Beyond the AbstractProstate CancerMay 20, 2026
-
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective - Beyond the AbstractProstate CancerMay 8, 2026
-
Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy - Beyond the AbstractProstate CancerMay 8, 2026
-
Inflammation and Insulin Profiles in Men Assigned to Exercise vs. Usual Care for Prostate Cancer: Results from the Active Surveillance Exercise (ASX) Randomized Controlled Trial - Beyond the AbstractProstate CancerMay 5, 2026
-
Pushing the Boundaries of SBRT in Irradiated Territories for Nodal Oligorecurrent Prostate Cancer: Outcomes of the CYGNUS Multicentric Retrospective Study - Beyond the AbstractProstate CancerMay 5, 2026